Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026

Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman, MD, will present at BIO-Europe Spring 2026 in Lisbon on March 24, 2026, from 1:30-1:45 p.m. WET in the Presentation Theatre A. The presentation will cover the company’s CNS and immunology programs and marketed products.

Key Figures

Conference dates: March 23–25, 2026 Presentation slot: March 24, 2026, 1:30–1:45 p.m. WET TONMYA dose: 2.8 mg +5 more

8 metrics

Conference dates March 23–25, 2026 BIO-Europe Spring 2026 in Lisbon

Presentation slot March 24, 2026, 1:30–1:45 p.m. WET Company presentation timing at BIO-Europe Spring 2026

TONMYA dose 2.8 mg Cyclobenzaprine HCl sublingual tablet strength for fibromyalgia

TONMYA indication gap More than 15 years First new fibromyalgia treatment for adults in this period

TONMYA development stage Phase 2 Trials in major depressive disorder and acute stress disorder

TNX-2900 stage Phase 2 ready For treatment of Prader-Willi syndrome

Share price $14.19 Pre-news price context on analysis date

Price change 10.32% 24-hour move ahead of this announcement

Market Reality Check

Price: $14.96 Vol: Volume 316,734 is close t...

normal vol

$14.96 Last Close

Volume Volume 316,734 is close to the 20-day average of 338,660, suggesting no unusual trading activity pre-announcement. normal

Technical Shares at 14.19 are trading below the 200-day MA of 25.57 and sit 79.72% below the 52-week high.

Peers on Argus

TNXP was up 10.32% while key biotech peers like NMRA, ANNX, CADL, OMER, and VNDA...

1 Up

TNXP was up 10.32% while key biotech peers like NMRA, ANNX, CADL, OMER, and VNDA showed declines between about 2–6%, indicating stock-specific strength rather than a broader peer rally.

Historical Context

5 past events · Latest: Mar 12 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Earnings results	Neutral	-1.3%	Reported 2025 financials, TONMYA launch metrics, cash balance, and capital raises.
Mar 10	Clinical data update	Positive	+1.6%	Post hoc Phase 3 TONMYA analyses showing rapid pain relief and strong risk–benefit profile.
Mar 09	Clinical data presentation	Positive	+1.6%	RESILIENT Phase 3 trial data for TONMYA presented at AAPM PainConnect meeting.
Mar 05	PK study publication	Positive	-2.0%	Phase 1 pharmacokinetic results for TONMYA showing rapid absorption and high early exposure.
Mar 03	Conference poster	Positive	+0.3%	Announcement of TONMYA poster on patient-centered outcomes at AAPM PainConnect.

Pattern Detected

Recent TNXP news has generally seen modest positive price alignment, with one notable divergence on favorable pharmacokinetic data.

Recent Company History

Over the past weeks, Tonix has highlighted commercialization and clinical progress for TONMYA, including Phase 3 data presentations and pharmacokinetic publications, plus 2025 earnings showing net product revenue of $13.1M. Most of these updates led to small positive moves, though the March 5 pharmacokinetic publication coincided with a -1.97% reaction. Today’s BIO-Europe Spring 2026 presentation fits into this pattern of ongoing visibility-building around TONMYA and the broader CNS portfolio.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-09-04

Tonix has an active S-3/A shelf registration dated 2025-09-04, with a recent 424B5 usage on 2025-11-21. The latest amendment re-filed an auditor consent exhibit and did not modify the prospectus terms, indicating the existing shelf structure remains in place.

Market Pulse Summary

This announcement centers on Tonix presenting at BIO-Europe Spring 2026, showcasing its commercial-s...

Analysis

This announcement centers on Tonix presenting at BIO-Europe Spring 2026, showcasing its commercial-stage TONMYA franchise and broader CNS and immunology pipeline, including Phase 2 programs and rare disease assets. Recent filings detailed TONMYA’s launch, revenue of $13.1M in 2025, and an active S-3/A shelf. Investors tracking this name often watch incremental prescription trends, progress of Phase 2 studies, additional partnership or conference exposure, and any new capital-raising activity as key future markers.

Key Terms

sublingual, fibromyalgia, major depressive disorder, acute stress disorder, +4 more

8 terms

sublingual medical

"cyclobenzaprine HCl sublingual tablets 2.8 mg"

Sublingual describes a way to take a drug or supplement by placing it under the tongue so active ingredients are absorbed through the thin tissue there directly into the bloodstream. Like taking a shortcut compared with swallowing a pill, this can produce faster effects, simpler dosing and sometimes more predictable delivery. Investors watch for sublingual formulations because they can affect a product’s market appeal, regulatory pathway, pricing and competitive positioning.

fibromyalgia medical

"first new treatment for fibromyalgia in adults in more than 15 years"

Fibromyalgia is a long-term condition that causes widespread body pain, extreme tiredness, and problems with sleep, memory and mood; people often feel unusually sensitive to normal touch or pressure, and symptoms can fluctuate from day to day. It matters to investors because it affects workforce productivity, healthcare spending, and demand for treatments—so advances in diagnostics, drugs, or care delivery can change market size and company prospects, much like a fuel problem that reduces a car’s performance and reliability.

major depressive disorder medical

"Phase 2 clinical trials to evaluate its potential in major depressive disorder"

A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.

acute stress disorder medical

"Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder"

Acute stress disorder is a short-term mental health reaction that can occur after a traumatic event, causing intense anxiety, flashbacks, sleep problems, and difficulty functioning for days to weeks. Think of it as an alarm system that stays stuck on after a scare; it matters to investors because it can drive demand for medical treatments and mental health services, influence insurance claims and workplace productivity, and affect regulatory or legal risks for companies.

prader-willi syndrome medical

"TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome"

A rare genetic disorder caused by missing or altered instructions on a specific chromosome that leads to constant hunger, low muscle tone, learning challenges, and hormonal problems; think of it as a faulty instruction manual that affects growth, appetite control, and development. Investors care because the condition creates a defined patient population, special regulatory incentives, and long-term medical needs that shape demand for therapies, diagnostics, and care services, influencing market size and risk for drug developers.

monoclonal antibody medical

"immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

cd40 ligand inhibitor medical

"TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection"

A CD40 ligand inhibitor is a drug that blocks the CD40 ligand, a protein used by immune cells to send activation and inflammatory signals; think of it as turning down an alarm bell that rallies the immune system. Investors care because these drugs aim to treat autoimmune diseases, transplant rejection or inflammatory conditions, so their clinical trial results, safety profile and regulatory approval prospects directly affect a company’s future revenue potential and development risk.

prophylaxis medical

"TNX-4800 for Lyme disease prophylaxis"

Prophylaxis is a medical prevention strategy — a drug, vaccine, device, or procedure given to stop a disease or condition before it starts. For investors, prophylactic products matter because they can create steady, large markets and reduce long‑term healthcare costs; regulatory approval or broader adoption can change demand forecasts much like a new safety feature that becomes standard across an entire industry.

AI-generated analysis. Not financial advice.

BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announced today that Seth Lederman, MD, Chief Executive Officer, will deliver a company presentation at BIO-Europe Spring 2026, being held March 23-25, 2026, in Lisbon, Portugal.

Company Presentation Details

Date and Time: Tuesday, March 24, 2026, 1:30-1:45 p.m. WET
Location: Presentation Theatre A
Presenter: Seth Lederman, MD, Chief Executive Officer

Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals* is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA^® (cyclobenzaprine HCl sublingual tablets 2.8 mg), is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace^® Symtouch^® (sumatriptan injection 3 mg) and Tosymra^® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA^® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X.

*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Brian Korb
astr partners
(917) 653-5122
brian.korb@astrpartners.com  

Media Contacts
Deborah Elson
Tonix Pharmaceuticals 
deborah.elson@tonixpharma.com

Ray Jordan
Putnam Insights
ray@putnaminsights.com  

FAQ

When and where will Tonix Pharmaceuticals (TNXP) present at BIO-Europe Spring 2026?

Tonix will present on March 24, 2026, 1:30–1:45 p.m. WET in Presentation Theatre A. According to Tonix Pharmaceuticals, CEO Seth Lederman, MD, will deliver the company presentation outlining its CNS and immunology portfolio.

What topics will Tonix (TNXP) likely cover in its BIO-Europe Spring 2026 presentation?

The presentation will focus on Tonix’s CNS and immunology pipeline and marketed products. According to Tonix Pharmaceuticals, topics include TONMYA, acute migraine products, TNX-2900, and immunology candidates like TNX-4800 and TNX-1500.

How can investors access Tonix Pharmaceuticals (TNXP) presentation materials or webcast from BIO-Europe Spring 2026?

Investors should check Tonix’s investor relations pages and social channels for access details. According to Tonix Pharmaceuticals, additional information and materials will be available on the company website and its LinkedIn and X accounts.

Does Tonix (TNXP) plan to discuss TONMYA clinical programs at BIO-Europe Spring 2026?

Yes, TONMYA’s development is part of the company’s CNS agenda and is expected to be discussed. According to Tonix Pharmaceuticals, TONMYA is being investigated in Phase 2 trials for major depressive disorder and acute stress disorder.

Will Tonix (TNXP) describe commercialized products like Zembrace Symtouch and Tosymra at the presentation?

Tonix is expected to highlight its commercial CNS infrastructure and marketed products. According to Tonix Pharmaceuticals, Zembrace Symtouch and Tosymra are part of the company’s marketed acute migraine portfolio supporting commercial operations.

Who is the presenter for Tonix Pharmaceuticals (TNXP) at BIO-Europe Spring 2026 and what is his role?

The presenter is Seth Lederman, MD, who serves as CEO of Tonix Pharmaceuticals. According to Tonix Pharmaceuticals, he will deliver the company presentation at the BIO-Europe Spring conference in Lisbon.